Progesterone and the risk of preterm birth among women with a short cervix

New England Journal of Medicine

Volumn 357, Issue 5, 2007, Pages 462-469

  Fonseca, Eduardo B ^a   Celik, Ebru ^a   Parra, Mauro ^a   Singh, Mandeep ^a   Nicolaides, Kypros H ^a,b  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; PROGESTERONE;

ABSENCE OF SIDE EFFECTS; ARTICLE; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELIVERY; FEMALE; GESTATIONAL AGE; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NEWBORN; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PREGNANT WOMAN; PREMATURE LABOR; PREMATURITY; PRENATAL CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK REDUCTION; TRANSVAGINAL ECHOGRAPHY; UTERINE CERVIX;

EID: 34547644454     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa067815     Document Type: Article

References (25)

1. Mathews TJ, Curtin SC, MacDorman MF. Infant mortality statistics from the 1998 period linked with birth/infant death data set. Natl Vital Stat Rep 2000;48(12):1-25.
2. Marlow N, Wolke D, Bracewell MA, Samara M. Neurologic and developmental disability at six years of age after extremely preterm birth. N Engl J Med 2005;352:9-19.
3. Veen S, Ens-Dokkum MH, Schreuder AM, Verloove-Vanhorick SP, Brand R, Ruys JH. Impairments, disabilities, and handicaps of very preterm and very-low-birthweight infants at five years of age: the Collaborative Project on Preterm and Small for Gestational Age Infants (POPS) in the Netherlands. Lancet 1991;338:33-6.
4. Meis PJ, Klebanoff M, Thom E, et al. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med 2003;348:2379-85. [Erratum, N Engl J Med 2003;349:1299.]
5. da Fonseca EB, Bittar RE, Carvalho MH, Zugaib M. Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebo-controlled double-blind study. Am J Obstet Gynecol 2003;188:419-24.
6. Dodd JM, Flenady V, Cincotta R, Crowther CA. Prenatal administration of progesterone for preventing preterm birth. Cochrane Database Syst Rev 2006;1:CD004947.
7. Mercer BM, Goldenberg RL, Moawad AH, et al. The preterm prediction study: effect of gestational age and cause of preterm birth on subsequent obstetric outcome. Am J Obstet Gynecol 1999;181:1216-21.
8. Iams JD, Goldenberg RL, Meis PJ, et al. The length of the cervix and the risk of spontaneous premature delivery. N Engl J Med 1996;334:567-72.
9. To MS, Fonseca EB, Molina FS, Cacho AM, Nicolaides KH. Maternal characteristics and cervical length in the prediction of spontaneous early preterm delivery in twins. Am J Obstet Gynecol 2006;194:1360-5.
10. To MS, Skentou CA, Royston P, Yu CK, Nicolaides KH. Prediction of patient-specific risk of early preterm delivery using maternal history and sonographic measurement of cervical length: a population-based prospective study. Ultrasound Obstet Gynecol 2006;27:362-7.
11. To MS, Skentou C, Chan C, Zagaliki A, Nicolaides KH. Cervical assessment at the routine 23-week scan: standardizing techniques. Ultrasound Obstet Gynecol 2001;17:217-9.
12. Introduction to stratified analysis. In: Greenland S, Rothman KJ. Modern epidemiology. 2nd ed. Philadelphia: Lippincott-Raven, 1998:253-80.
13. Hosmer DW Jr, Lemeshow S. Applied logistic regression. 2nd ed. New York: John Wiley, 2000.
14. Hosmer DWLS. Applied survival analysis: regression modeling of time to event data. New York: John Wiley, 1999.
15. Grambsch PMTT. Proportional hazards tests and diagnositics based on weighted residuals. Biometrika 1994;81:515-26.
16. Zhang J, Yu KF. What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. JAMA 1998;280:1690-1.
17. Data from Office of Population Census and Surveys: NHS maternity statistics, England: 2002-2003. London: Department of Health Statistical Office, 2004.
18. Rouse DJ, Caritis SN, Peaceman AM, et al. A trial of 17 alpha-hydroxyprogesterone caproate to prevent prematurity in twins. N Engl J Med 2007;357:454-61.
19. Miles RA, Paulson RJ, Lobo RA, Press MF, Dahmoush L, Sauer MV. Pharmacokinetics and endometrial tissue levels of progesterone after administration by intramuscular and vaginal routes: a comparative study. Fertil Steril 1994;62:485-90.
20. Friedler S, Raziel A, Schachter M, Strassburger D, Bukovsky I, Ron-El R. Luteal support with micronized progesterone following in-vitro fertilization using a down-regulation protocol with gonadotrophin-releasing hormone agonist: a comparative study between vaginal and oral administration. Hum Reprod 1999;14:1944-8.
21. ACOG committee opinion: use of progesterone to reduce preterm birth. Obstet Gynecol 2003;102:1115-6.
22. Brent RL. Nongenital malformations following exposure to progestational drugs: the last chapter of an erroneous allegation. Birth Defects Res A Clin Mol Teratol 2005;73:906-18.
23. Hendrickx AG, Korte R, Leuschner F, et al. Embryotoxicity of sex steroidal hormones in nonhuman primates. II. Hydroxyprogesterone caproate, estradiol valerate. Teratology 1987;35:129-36.
24. Heath VC, Southall TR, Souka AP, Novakov A, Nicolaides KH. Cervical length at 23 weeks of gestation: relation to demographic characteristics and previous obstetric history. Ultrasound Obstet Gynecol 1998;12:304-11.
25. Clement S, Candy B, Heath V, To M, Nicolaides KH. Transvaginal ultrasound in pregnancy: its acceptability to women and maternal psychological morbidity. Ultrasound Obstet Gynecol 2003;22:508-14.